IPO Issue Details
Issue Price / Price Band₹61 per share (Fixed Price)
Face Value₹10 Per Share
Lot Size2,000 Shares per Lot
Total Issue Size29,78,000 shares (aggregating up to ₹18.17 Cr)
Issue TypeFixed Price IPO
Sale Type / CategoryFresh Capital
Exchange / PlatformNSE SME
IPO TypeSME
Subscription OpenThu, 25 Aug 2022
Subscription CloseTue, 30 Aug 2022
Anchor AllotmentWed, 24 Aug 2022
Basis of AllotmentMon, 05 Sep 2022
Initiation of RefundsTue, 06 Sep 2022
Credit of Shares to DematWed, 07 Sep 2022
Listing DateThu, 08 Sep 2022
UPI Mandate Deadline2022-08-30
Application & Investment Details
Retail — Min (1 Lots)₹1,22,000 — 2,000 shares
Retail — Max (13 Lots)₹1,586,000 (13 Lots)
HNI — Min (2 Lots)₹2,44,000 — 4,000 shares
P/E Ratio (Pre-IPO)26.52x
Net Offer to Public28,28,000 shares (aggregating up to ₹17.25 Cr)
Reserved for Market Maker1,50,000 shares (aggregating up to ₹0.9150 Cr)
Pre-IPO Promoter Holding80,20,441 shares
Post-IPO Promoter Holding1,09,98,441 shares
About JFL Life Sciences Ltd.
Incorporated in 2010, JFL Life Sciences Limited is engaged in the business of manufacturing of pharmaceutical products. The company's product portfolio consists of Dry powder injections (B-Lactam), Tablets & Capsules (B-Lactam) solid oral dosage form and Tablet and capsules (general) Solid Oral Dosage Form and Oral rehydration solutions (ORS).The company's sales strategy is to sell the products in bulk to pharmaceutical marketers and traders who in turn provide the channel for sales to customers. JFL Life Sciences Limited has a market presence in PAN India and JFL's products are supplied to 10 developed and developing countries throughout the World.JFL Life Sciences Limited exports products to African, Middle Eastern, and CIS countries, mainly through merchant exporters. The company is registered with the MOH of Kenya, Nigeria, Yemen, Cambodia & Myanmar for manufacturing a particular product. Few of our products are also registered with Ukraine, Uzbekistan, and Kazakhstan (CIS countries) through merchants.JFL has two manufacturing units (on lease) in Gujarat.Competitive Strength :Product registrationExperienced management and dedicated employee baseQuality assuranceQuality & Brand strength
Objects of the Issue
JFL Life Sciences Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
1
Repayment of secured and unsecured loans.
2
Funding the working capital requirements of the company.
3
General Corporate Purposes
Shareholding & Lock-in
Pre-IPO Promoter Holding
80,20,441 shares
Post-IPO Promoter Holding
1,09,98,441 shares